Cartiva Implant Lawsuit Updates & News (2025)

Stryker has recalled all Cartiva synthetic cartilage implants sold since 2016 due to failure rates up to 79% within two years. Intended as an alternative to big toe fusion for arthritis, the implants have caused complications like displacement and fragmentation, often requiring removal surgeries.

All implant sizes are included in the recall. Healthcare providers must return unused devices and closely monitor patients for pain, swelling, or stiffness. Affected patients should contact Stryker and the FDA.

Lawsuits against Stryker are rising, alleging defective design, inadequate testing, and prioritizing profits over safety. Plaintiffs are calling for settlements as the issues with the implants become more apparent.

As of 2023, the Cartiva Implant Lawsuits have started to gain significant traction, with a growing number of affected patients and their families seeking legal recourse. The central allegations of these lawsuits are that Cartiva Inc., Wright Medical Group, and Stryker, the manufacturers and distributors of the Cartiva Implant, were aware of the high failure rate and potential complications of the device, but withheld this critical information to avoid a product recall and protect their profits.

These lawsuits claim that the manufacturers failed in their duty to ensure the safety and effectiveness of their product, leading to widespread patient suffering. The victims are now seeking justice and compensation for their pain, suffering, medical expenses, and loss of income resulting from additional surgeries and recovery periods.

In addition to individual lawsuits, there is a growing momentum towards forming a class-action lawsuit. A class-action lawsuit allows a group of people who have suffered similar harm to join together to sue the responsible party. This approach can be particularly effective when the damages for each individual may not be substantial enough to justify the costs of individual lawsuits.